ArticleInternational journal of general medicine2025
Analysis of OCT-Based Biomarkers and Recurrence in Eyes with Diabetic Macular Edema Following Anti-VEGF Therapy.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify pre-treatment optical coherence tomography (OCT) biomarkers predictive of recurrence in eyes with diabetic macular edema (DME) after anti-VEGF therapy. Methods: This retrospective cohort study included 122 eyes with DME treated with anti-VEGF monotherapy (ranibizumab; Novartis Pharma Schweiz AG, Basel, Switzerland) at Pinghu First People's Hospital (January 2020 - December 2023). The treatment protocol consisted of 3 monthly loading doses followed by a pro re nata (PRN) regimen. Patients were stratified into recurrence (n=54) and non-recurrence (n=68) groups based on predefined criteria during 12 months of follow-up. Baseline OCT parameters were compared, and multivariate logistic regression was used to identify independent predictors. A combined model's predictive performance was assessed using receiver operating characteristic (ROC) curve analysis. Results: The recurrence group had significantly higher baseline central retinal thickness (452.7±84.3 vs 391.5±70.2 μm, P=0.002), subretinal fluid (SRF) prevalence (63.0% vs 36.8%, P=0.008), proportion with ≥5 hyperreflective foci (HRF) (68.5% vs 35.3%, P<0.001), and ellipsoid zone (EZ) disruption rate (57.4% vs 30.9%, P=0.006), and required more injections (6.4±1.3 vs 4.8±1.2, P<0.001). Multivariate analysis confirmed HRF ≥5 (OR=3.52, P<0.001), SRF presence (OR=2.89, P=0.007), and EZ disruption (OR=2.41, P=0.023) as independent risk factors. Their combined model predicted recurrence with an AUC of 0.841. Conclusion: HRF, SRF, and EZ integrity are key OCT biomarkers for DME recurrence. A combined model aids risk stratification for personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.